Evidence map›Paper›PMID 39833612›Full record

ArticleNature metabolism2025

Targeting aldolase A in hepatocellular carcinoma leads to imbalanced glycolysis and energy stress due to uncontrolled FBP accumulation.

Marteinn T Snaebjornsson, Philipp Poeller, Daria Komkova, Florian Röhrig, Lisa Schlicker, Alina M Winkelkotte, Adriano B Chaves-Filho, Kamal M Al-Shami, Carolina Dehesa Caballero, Ioanna Koltsaki and 8 more

Abstract read
In one paragraph

Article in Nature metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Fe metal-organic framework-derived heterojunction for metabolic diagnosis of thymic epithelial tumor.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. A Covalent PFKL Activator Suppresses Tumor Growth.bioRxiv : the preprint server for biology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marteinn T SnaebjornssonDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0009-0008-4457-5726
Philipp PoellerDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-3924-5756
Daria KomkovaInstitute for Theoretical Biology, Humboldt University of Berlin, Berlin, Germany.
Florian RöhrigDepartment of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, University of Würzburg, Würzburg, Germany.
Lisa SchlickerDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8350-2289
Alina M WinkelkotteDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-7728-0715
Adriano B Chaves-FilhoDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kamal M Al-ShamiDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Carolina Dehesa CaballeroDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ioanna KoltsakiDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Felix C E VogelDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4067-2074
Roberto Carlos Frias-SolerDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0942-9463
Ramona RudalskaDepartment of Medical Oncology and Pneumology, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-1742-0912
Jessica D SchwarzDepartment of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, University of Würzburg, Würzburg, Germany.
Elmar WolfDepartment of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, University of Würzburg, Würzburg, Germany.
Daniel DauchDepartment of Medical Oncology and Pneumology, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-9805-5784
Ralf SteuerInstitute for Theoretical Biology, Humboldt University of Berlin, Berlin, Germany.
Almut SchulzeDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany. almut.schulze@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0002-8199-6422

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) SMART-NAFLDDeutsche Forschungsgemeinschaft (German Research Foundation) 453048493Deutsche Forschungsgemeinschaft (German Research Foundation) FOR-2314Deutsche Forschungsgemeinschaft (German Research Foundation) FOR-2314, EXC 2180-390900677Deutsche Forschungsgemeinschaft (German Research Foundation) SPP-2306Deutsche Krebshilfe (German Cancer Aid) 70114554
6 · The paper itself

Abstract

Increased glycolytic flux is a hallmark of cancer; however, an increasing body of evidence indicates that glycolytic ATP production may be dispensable in cancer, as metabolic plasticity allows cancer cells to readily adapt to disruption of glycolysis by increasing ATP production via oxidative phosphorylation. Using functional genomic screening, we show here that liver cancer cells show a unique sensitivity toward aldolase A (ALDOA) depletion. Targeting glycolysis by disrupting the catalytic activity of ALDOA led to severe energy stress and cell cycle arrest in murine and human hepatocellular carcinoma cell lines. With a combination of metabolic flux analysis, metabolomics, stable-isotope tracing and mathematical modelling, we demonstrate that inhibiting ALDOA induced a state of imbalanced glycolysis in which the investment phase outpaced the payoff phase. Targeting ALDOA effectively converted glycolysis from an energy producing into an energy-consuming process. Moreover, we found that depletion of ALDOA extended survival and reduced cancer cell proliferation in an animal model of hepatocellular carcinoma. Thus, our findings indicate that induction of imbalanced glycolysis by targeting ALDOA presents a unique opportunity to overcome the inherent metabolic plasticity of cancer cells.

Indexed as

Carcinoma, HepatocellularEnergy MetabolismFructose-Bisphosphate AldolaseGlycolysisLiver NeoplasmsAnimalsCell Line, TumorCell ProliferationHumansMiceFructose-Bisphosphate Aldolase

Identifiers

PMID39833612
PMCPMC11860237

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.